Target Information
Target General Infomation | |||||
---|---|---|---|---|---|
Target ID |
T69619
|
||||
Former ID |
TTDR00742
|
||||
Target Name |
Membrane copper amine oxidase
|
||||
Gene Name |
AOC3
|
||||
Synonyms |
HPAO; VAP-1; Vascular adhesion protein-1; AOC3
|
||||
Target Type |
Successful
|
||||
Disease | Atopic dermatitis [ICD9: 691.8, 692.9; ICD10: L00-L99] | ||||
Asthma [ICD10: J45] | |||||
Central nervous system disease [ICD10: G00-G99] | |||||
Cerebrovascular ischaemia [ICD9: 434.91; ICD10: I61-I63] | |||||
Diabetes [ICD9: 253.5, 588.1; ICD10: E23.2, N25.1] | |||||
Hypertension [ICD9: 401; ICD10: I10-I16] | |||||
Inflammatory disease [ICD9: 140-229, 147, 173, 573.3, 710-719; ICD10: C11, C44, K75.9, M00-M25] | |||||
Psoriasis [ICD9: 696; ICD10: L40] | |||||
Pulmonary disease [ICD9: 460-519; ICD10: J00-J99] | |||||
Vascular disease [ICD9: 325, 430-459; ICD10: G45-G46, I60-I95] | |||||
Function |
Cell adhesion protein that participates in lymphocyte extravasation and recirculation by mediating the binding of lymphocytes to peripheral lymph node vascular endothelial cells in an L-selectin-independent fashion. Has semicarbazide-sensitive (SSAO) monoamine oxidase activity. May play a role in adipogenesis.
|
||||
BioChemical Class |
Oxidoreductases acting on CH-NH2 group of donors
|
||||
UniProt ID | |||||
EC Number |
EC 1.4.3.21
|
||||
Sequence |
MNQKTILVLLILAVITIFALVCVLLVGRGGDGGEPSQLPHCPSVSPSAQPWTHPGQSQLF
ADLSREELTAVMRFLTQRLGPGLVDAAQARPSDNCVFSVELQLPPKAAALAHLDRGSPPP AREALAIVFFGRQPQPNVSELVVGPLPHPSYMRDVTVERHGGPLPYHRRPVLFQEYLDID QMIFNRELPQASGLLHHCCFYKHRGRNLVTMTTAPRGLQSGDRATWFGLYYNISGAGFFL HHVGLELLVNHKALDPARWTIQKVFYQGRYYDSLAQLEAQFEAGLVNVVLIPDNGTGGSW SLKSPVPPGPAPPLQFYPQGPRFSVQGSRVASSLWTFSFGLGAFSGPRIFDVRFQGERLV YEISLQEALAIYGGNSPAAMTTRYVDGGFGMGKYTTPLTRGVDCPYLATYVDWHFLLESQ APKTIRDAFCVFEQNQGLPLRRHHSDLYSHYFGGLAETVLVVRSMSTLLNYDYVWDTVFH PSGAIEIRFYATGYISSAFLFGATGKYGNQVSEHTLGTVHTHSAHFKVDLDVAGLENWVW AEDMVFVPMAVPWSPEHQLQRLQVTRKLLEMEEQAAFLVGSATPRYLYLASNHSNKWGHP RGYRIQMLSFAGEPLPQNSSMARGFSWERYQLAVTQRKEEEPSSSSVFNQNDPWAPTVDF SDFINNETIAGKDLVAWVTAGFLHIPHAEDIPNTVTVGNGVGFFLRPYNFFDEDPSFYSA DSIYFRGDQDAGACEVNPLACLPQAAACAPDLPAFSHGGFSHN |
||||
Drugs and Mode of Action | |||||
Inhibitor | 2,6-DICHLORO-N-IMIDAZOLIDIN-2-YLIDENEANILINE | Drug Info | [551374] | ||
6-hydroxydopa quinone | Drug Info | [551393] | |||
FP-1102 | Drug Info | [543706] | |||
LJP-1207 | Drug Info | [543706] | |||
PSX-4206 | Drug Info | [543706] | |||
PXS-4159 | Drug Info | [543706] | |||
RTU-1096 | Drug Info | [543706] | |||
Vapill | Drug Info | [543706] | |||
Modulator | Hydralazine | Drug Info | [556264] | ||
VAP-1 | Drug Info | [543706] | |||
Target Expression Profile (TEP) and Drug Resistance Mutation (DRM) | |||||
TEP | EXP Info | ||||
Pathways | |||||
BioCyc Pathway | Phenylethylamine degradation I | ||||
Spermine and spermidine degradation I | |||||
KEGG Pathway | Glycine, serine and threonine metabolism | ||||
Tyrosine metabolism | |||||
Phenylalanine metabolism | |||||
beta-Alanine metabolism | |||||
Metabolic pathways | |||||
PANTHER Pathway | Phenylethylamine degradation | ||||
PathWhiz Pathway | Beta-Alanine Metabolism | ||||
References | |||||
Ref 524913 | ClinicalTrials.gov (NCT02239211) A Trial of BTT1023 in Patients With Primary Sclerosing Cholangitis. U.S. National Institutes of Health. | ||||
Ref 542349 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7326). | ||||
Ref 532422 | Preclinical evaluation of a radioiodinated fully human antibody for in vivo imaging of vascular adhesion protein-1-positive vasculature in inflammation. J Nucl Med. 2013 Aug;54(8):1315-9. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.